US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Septerna, Inc.

7.05

+0.60009.30%

Post-market: 7.050.00000.00%16:20 EDT

Volume:178.29K

Turnover:1.24M

Market Cap:313.32M

PE:-0.97

High:7.13

Open:6.56

Low:6.45

Close:6.45

Loading ...

Overview Company News Filings

US Stocks Mixed; NY State Business Activity Rises In February

BUZZ-Septerna slumps after scrapping trial of hormonal disorder drug

Septerna Discontinues Phase 1 Trial of SEP-786 for Hypoparathyroidism; Shares Fall Pre-Bell

MT Newswires Live

Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism

Septerna Inc: Advancing Multiple Next-Generation Pth1r Agonists With Distinct and Unrelated Chemical Structures Relative to SEP-786

THOMSON REUTERS

Septerna Inc - No Liver Injury or Serious Adverse Events in Phase 1 Trial

THOMSON REUTERS

Septerna Inc - Expects Cash Position to Support Operations Into 2027

THOMSON REUTERS

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule Pth1r Agonist

THOMSON REUTERS

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Septerna Price Target Maintained With a $50.00/Share by Cantor Fitzgerald

Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Septerna Names Gil Labrucherie Finance Chief

MT Newswires Live

Septerna Brings in Gil Labrucherie as Finance Chief

Septerna Expands Leadership With Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

THOMSON REUTERS

Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

Top Premarket Decliners

MT Newswires Live

Septerna, Inc. Reports Q3 2024 Financials and Progress

BRIEF-Septerna-Phase 1 Clinical Trial Ongoing For SEP-786, Oral Small Molecule For Hypoparathyroidism, With Data Expected In Mid-2025

Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SEPN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SEPN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","market":"US","secType":"STK","nameCN":"Septerna, Inc.","latestPrice":7.05,"timestamp":1746648000000,"preClose":6.45,"halted":0,"volume":178290,"hourTrading":{"tag":"盘后","latestPrice":7.05,"preClose":7.05,"latestTime":"16:20 EDT","volume":94,"amount":662.7,"timestamp":1746649200558},"delay":0,"floatShares":19629894,"shares":44442496,"eps":-7.26,"marketStatus":"Not Yet Opened","change":0.6,"latestTime":"05-07 16:00:00 EDT","open":6.56,"high":7.13,"low":6.4501,"amount":1235783.1362,"amplitude":0.105411,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.26,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746691200000},"marketStatusCode":0,"adr":0,"listingDate":1729828800000,"exchange":"NASDAQ","adjPreClose":6.45,"preHourTrading":{"tag":"盘前","latestPrice":6.55,"preClose":6.45,"latestTime":"08:23 EDT","volume":1,"amount":6.55,"timestamp":1746620626310},"postHourTrading":{"tag":"盘后","latestPrice":7.05,"preClose":7.05,"latestTime":"16:20 EDT","volume":94,"amount":662.7,"timestamp":1746649200558},"volumeRatio":0.860646,"impliedVol":0.4308,"impliedVolPercentile":0.1356},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SEPN\",,,,,undefined,":{"symbol":"SEPN","floatShares":19629894,"roa":"-17.20%","roe":"-27.05%","lyrEps":-7.258829,"volumeRatio":0.860646,"shares":44442496,"dividePrice":0,"high":7.13,"amplitude":0.105411,"preClose":6.45,"low":6.4501,"week52Low":4.17,"pbRate":"0.75","psRate":"291.46","week52High":28.99,"institutionHeld":0,"latestPrice":7.05,"eps":-7.26,"divideRate":0,"volume":178290,"delay":0,"ttmEps":-7.26,"open":6.56,"prevYearClose":22.9,"prevWeekClose":7.48,"prevMonthClose":6.96,"prevQuarterClose":5.79,"fiveDayClose":6.96,"twentyDayClose":5.02,"sixtyDayClose":13.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SEPN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512166397","title":"US Stocks Mixed; NY State Business Activity Rises In February","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166397","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512166397?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:45","pubTimestamp":1739889914,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43784079/us-stocks-mixed-ny-state-business-activity-rises-in-february","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1894683264.USD","LU1883839398.USD","PTPI","IE00BGHQF748.EUR","LU0061475181.USD","BK4139","TSYW.SI","HCTI","NQmain","USAW.SI","TQQQ","BK4135","QLD","PSQ","USJW.SI","BK4007","IE0034235188.USD","QID","IE00B64PRP62.GBP","PRFX","SEPN","BK4167","SQQQ","KWE","LU1894683348.USD","NVIW.SI","MNQmain","IE00B3QW5Z07.USD","STT","BPTH",".IXIC","BK4187","BK4588"],"gpt_icon":1},{"id":"2512546168","title":"BUZZ-Septerna slumps after scrapping trial of hormonal disorder drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2512546168","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512546168?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:06","pubTimestamp":1739887606,"startTime":"0","endTime":"0","summary":"BUZZ-Septerna slumps after scrapping trial of hormonal disorder drug ** Drug developer Septerna's shares SEPN.O fall 66.6% to $4.49 premarket** Co discontinues an early-stage trial of its experimental","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nL3N3P9118:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2512508091","title":"Septerna Discontinues Phase 1 Trial of SEP-786 for Hypoparathyroidism; Shares Fall Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2512508091","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512508091?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:44","pubTimestamp":1739886251,"startTime":"0","endTime":"0","summary":"Septerna  shares were down sharply premarket Tuesday after the company said it has discontinued a phase 1 clinical trial of SEP-786 for the potential treatment of hypoparathyroidism in healthy volunteers.The company said the decision follows two unanticipated severe events of elevated unconjugated bilirubin in a portion of the trial, though there were no occurrences of liver injury, cholestasis, or hemolysis among participants and no serious adverse events.The company said its cash, cash equivalents, and marketable securities totaled $137.5 million as of Sept. 30. Together with $302.6 million in net proceeds from its October IPO, Septerna said it expects its current cash position to support operations into at least H2 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2512152957","title":"Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2512152957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512152957?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:05","pubTimestamp":1739883926,"startTime":"0","endTime":"0","summary":"Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy voluntee...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/septerna-discontinues-sep-786-phase-1-clinical-trial-in-hypoparathyroidism?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/septerna-discontinues-sep-786-phase-1-clinical-trial-in-hypoparathyroidism?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2512547231","title":"Septerna Inc: Advancing Multiple Next-Generation Pth1r Agonists With Distinct and Unrelated Chemical Structures Relative to SEP-786","url":"https://stock-news.laohu8.com/highlight/detail?id=2512547231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512547231?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA3HTX69:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2512154784","title":"Septerna Inc - No Liver Injury or Serious Adverse Events in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512154784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512154784?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA3HTX69:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2512154759","title":"Septerna Inc - Expects Cash Position to Support Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2512154759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512154759?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA3HTX69:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2512154731","title":"Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule Pth1r Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2512154731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512154731?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250218:nTUA3HTX69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2512850152","title":"Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2512850152","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512850152?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3027803/0/en/Septerna-Announces-Discontinuation-of-SEP-786-Phase-1-Clinical-Trial-and-Plans-to-Advance-Next-Generation-Oral-Small-Molecule-PTH1R-Agonist.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4007"],"gpt_icon":0},{"id":"2510638333","title":"Septerna Price Target Maintained With a $50.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2510638333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510638333?lang=en_us&edition=fundamental","pubTime":"2025-02-11 23:08","pubTimestamp":1739286480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SEPN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2025 10:08 ET (15:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN"],"gpt_icon":0},{"id":"2509994275","title":"Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2509994275","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509994275?lang=en_us&edition=fundamental","pubTime":"2025-02-06 20:48","pubTimestamp":1738846135,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now.In this article, we are going to take a look at where Septerna, Inc.  stands against the other rebound stocks.The United States economy is in a constant state of flux. In recent weeks, moderated growth, evolving monetary policies, and significant trade developments have impacted the overall outlook for the economy. The Organisation for Economic Co-operation and Development  anticipates a deceleration in US economic growth, projecting a decrease from 2.6% in 2024 to 1.6% in 2025. This slowdown is expected to be mitigated by monetary policy easing, with policy interest rates projected to decline by an additional 1.5 percentage points by the end of 2025, aligning rates toward neutral levels. Contrastingly, Goldman Sachs offers a more optimistic outlook, forecasting a 2.5% growth in US GDP for 2025, surpassing the consensus estimate of 1.9%. Chief US Economist David Mericle emphasizes the diminishing recession fears","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/septerna-inc-sepn-among-best-124855417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443465.HKD","BK4127","LU2237443622.USD","IE0034235188.USD","LU2237443382.USD","BK4007","IE00BSNM7G36.USD","LU2237443895.HKD","BK4504","SQQQ","IE00BFXG1179.USD",".IXIC","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU2237438978.USD","TQQQ","BK4550","BK4552","BK4516","QID","BK4585","USAW.SI","NVIW.SI","BK4533","USJW.SI","LU1791807156.HKD","SEPN","LU2237443978.SGD","MNQmain","QLD","IE0004086264.USD","TSYW.SI","LU2237443549.SGD","IE0004091025.USD","PSQ","LU0106831901.USD","NQmain","LU1668664300.SGD"],"gpt_icon":1},{"id":"2501751583","title":"Third Rock-backed Maze Therapeutics reveals profit in US IPO filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501751583","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501751583?lang=en_us&edition=fundamental","pubTime":"2025-01-08 06:57","pubTimestamp":1736290652,"startTime":"0","endTime":"0","summary":"Third Rock-backed Maze Therapeutics reveals profit in US IPO filing Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nL4N3O31NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BCAX","SEPN","SIVBQ","BK4139","BK4207","BK4589","BK4585","BK4211","BK4007"],"gpt_icon":0},{"id":"2501235422","title":"Septerna Names Gil Labrucherie Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2501235422","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501235422?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:35","pubTimestamp":1736166932,"startTime":"0","endTime":"0","summary":"Septerna (SEPN) said Monday it has named Gil Labrucherie chief financial officer.Labrucherie, who has more than 25 years of experience, most recently served as Acelyrin's (SLRN) chief financial officer and chief business officer, Septerna said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLRN","SEPN","BK4007","BK4139"],"gpt_icon":0},{"id":"2501235668","title":"Septerna Brings in Gil Labrucherie as Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2501235668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501235668?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:25","pubTimestamp":1736166300,"startTime":"0","endTime":"0","summary":"Clinical-stage biotech company Septerna appointed Gil Labrucherie as chief financial officer.Labrucherie most recently served as CFO and chief business officer at Acelyrin. He has more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies.Chief Executive Jeffrey Finer said Labrucherie's experience will be pivotal as Septerna continues to scale the company as it advances SEP-786 and its broader pipeline of oral small molecule G protein-coupled receptor programs, among other efforts.Labrucherie will receive an annual base salary of $485,000 and is eligible to earn an annual target bonus of 40% of his annual base salary, according to a securities filing.Ran Xiao will resign as the interim CFO, principal financial officer and principal accounting officer in connection with Labrucherie's appointment. She will continue to serve as vice president of finance and business operations.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2501823844","title":"Septerna Expands Leadership With Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501823844","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501823844?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA80NLM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2501238174","title":"Press Release: Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2501238174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501238174?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164800,"startTime":"0","endTime":"0","summary":"Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company's finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar's Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4099","BK4555","SEPN","TM","BK4585","BK4588","GPCR","BK4007","03160"],"gpt_icon":0},{"id":"2495549449","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2495549449","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495549449?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:47","pubTimestamp":1735562846,"startTime":"0","endTime":"0","summary":"Repay Holdings  shares slumped 22% pre-bell Monday following a 1.7% loss in the previous session.DallasNews Corporation  shares fell 19%, reversing from Friday's gains.Design Therapeutics  shares decreased 16% after a 3.7% loss on Friday.Chicago Rivet & Machine  shares slid 13% after a 2.5% drop.Septerna  shares were down 13%, adding to Friday's 1.7% loss.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RPAY","CVR","LU1861217088.USD","BK4227","CVR.AU","SEPN","BK4539","BK4161","BK4111","LU1861220207.SGD","BK4505","DALN","BK4007","BK4139","BK4106","DSGN","BK7095"],"gpt_icon":0},{"id":"2485482970","title":"Septerna, Inc. Reports Q3 2024 Financials and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2485482970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485482970?lang=en_us&edition=fundamental","pubTime":"2024-11-21 12:12","pubTimestamp":1732162320,"startTime":"0","endTime":"0","summary":"Septerna, Inc. ( ($SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors. Septerna...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/septerna-inc-reports-q3-2024-financials-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/septerna-inc-reports-q3-2024-financials-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","SEPN","PRGS","BK4097","BK4007"],"gpt_icon":0},{"id":"2485017449","title":"BRIEF-Septerna-Phase 1 Clinical Trial Ongoing For SEP-786, Oral Small Molecule For Hypoparathyroidism, With Data Expected In Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2485017449","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485017449?lang=en_us&edition=fundamental","pubTime":"2024-11-21 06:25","pubTimestamp":1732141546,"startTime":"0","endTime":"0","summary":"BRIEF-Septerna-Phase 1 Clinical Trial Ongoing For SEP-786, Oral Small Molecule For Hypoparathyroidism, With Data Expected In Mid-2025Nov 20 (Reuters) - Septerna Inc SEPN.O:SEPTERNA-PHASE 1 CLINICAL TR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SEPN"],"gpt_icon":0},{"id":"2485173237","title":"Septerna-Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, With Data Expected in Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2485173237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485173237?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:13","pubTimestamp":1732137186,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0WA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SEPN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":59,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SEPN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"SEPN","fiscalQuarterEnding":"2024/12","expectedEps":-0.69,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.64}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SEPN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SEPN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.75,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1739937600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SEPN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SEPN","date":"2025-05-06","current":-4.431994,"percent":0.666667,"low":-71.269737,"twenty":-60.215544,"median":-17.448232,"eighty":-3.575306,"high":261.261398,"avg":2.935847,"sd":94.042124,"marketCap":318208271},"quantilePoints":[{"date":"2024-10-25","current":180.873276,"twenty":180.873276,"median":180.873276,"eighty":180.873276,"marketCap":756050292},{"date":"2024-10-31","current":204.688257,"twenty":197.111676,"median":204.688257,"eighty":209.813,"marketCap":855596913},{"date":"2024-11-08","current":261.261398,"twenty":203.984861,"median":216.997688,"eighty":242.57116,"marketCap":1092072644},{"date":"2024-11-15","current":224.885772,"twenty":207.743006,"median":230.613426,"eighty":256.156752,"marketCap":940022529},{"date":"2024-11-22","current":-56.371082,"twenty":203.984861,"median":228.503238,"eighty":245.706296,"marketCap":915240881},{"date":"2024-11-29","current":-69.163916,"twenty":-57.105794,"median":221.92146,"eighty":240.581553,"marketCap":1122945345},{"date":"2024-12-06","current":-68.890433,"twenty":-66.926823,"median":208.506693,"eighty":237.707678,"marketCap":1118505070},{"date":"2024-12-13","current":-61.725172,"twenty":-67.501138,"median":191.022276,"eighty":236.763117,"marketCap":1002169886},{"date":"2024-12-20","current":-63.995083,"twenty":-66.784612,"median":-58.207863,"eighty":234.592638,"marketCap":1039024162},{"date":"2024-12-27","current":-70.449288,"twenty":-68.420042,"median":-60.166317,"eighty":232.180994,"marketCap":1143814633},{"date":"2025-01-03","current":-58.388676,"twenty":-68.655237,"median":-61.232902,"eighty":229.769351,"marketCap":947998541},{"date":"2025-01-10","current":-57.02126,"twenty":-67.714455,"median":-60.412452,"eighty":226.39305,"marketCap":925797170},{"date":"2025-01-17","current":-46.437457,"twenty":-67.358927,"median":-58.853597,"eighty":224.885772,"marketCap":753958559},{"date":"2025-01-24","current":-50.266223,"twenty":-66.593173,"median":-57.614562,"eighty":220.142874,"marketCap":816122397},{"date":"2025-01-31","current":-48.433885,"twenty":-66.401735,"median":-55.982023,"eighty":215.822012,"marketCap":786372560},{"date":"2025-02-07","current":-38.861971,"twenty":-65.110894,"median":-50.840537,"eighty":209.813,"marketCap":630962963},{"date":"2025-02-14","current":-31.587316,"twenty":-64.153703,"median":-49.199638,"eighty":205.451944,"marketCap":512851670},{"date":"2025-02-21","current":-16.108164,"twenty":-63.748948,"median":-46.492154,"eighty":202.578068,"marketCap":261532150},{"date":"2025-02-28","current":-15.862029,"twenty":-63.55204,"median":-46.410109,"eighty":188.992476,"marketCap":257535903},{"date":"2025-03-07","current":-17.393535,"twenty":-63.169163,"median":-46.191322,"eighty":63.291545,"marketCap":282401439},{"date":"2025-03-14","current":-17.47558,"twenty":-62.928498,"median":-43.237703,"eighty":-15.145503,"marketCap":283733521},{"date":"2025-03-21","current":-16.81922,"twenty":-62.747999,"median":-39.764466,"eighty":-15.424456,"marketCap":273076863},{"date":"2025-03-28","current":-3.893469,"twenty":-62.08617,"median":-37.439858,"eighty":-15.424456,"marketCap":279543299},{"date":"2025-04-04","current":-3.590162,"twenty":-61.462628,"median":-35.44343,"eighty":-3.701581,"marketCap":257766476},{"date":"2025-04-11","current":-3.194007,"twenty":-61.271189,"median":-31.04035,"eighty":-3.397655,"marketCap":229323279},{"date":"2025-04-17","current":-3.707771,"twenty":-61.249311,"median":-18.610536,"eighty":-3.429843,"marketCap":266210551},{"date":"2025-04-25","current":-3.998698,"twenty":-60.904722,"median":-17.913153,"eighty":-3.49979,"marketCap":287098524},{"date":"2025-05-02","current":-4.419614,"twenty":-60.313998,"median":-17.530277,"eighty":-3.557975,"marketCap":317319421},{"date":"2025-05-06","current":-4.431994,"twenty":-60.215544,"median":-17.448232,"eighty":-3.575306,"marketCap":318208271}],"updateTime":1746684055445}}}